CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Vinodh Pillai(Children's Hospital of Philadelphia), Susan R. Rheingold(Children's Hospital of Philadelphia)
Cited by 201
Related Papers
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
|Leukemia|2018|209
CD5 deletion enhances the antitumor activity of adoptive T cell therapies
|Science Immunology|2024|45